ARMP trades 111.9% below Wall Street's consensus target of $15.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ARMP achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, Armata Pharmaceuticals, Inc. (ARMP) has a Wall Street consensus price target of $15.00, based on estimates from 4 covering analysts. With the stock currently trading at $6.87, this represents a potential upside of +111.9%. The company has a market capitalization of $252M.
Analyst price targets range from a low of $15.00 to a high of $15.00, representing a 0% spread in expectations. The median target of $15.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ARMP trades at a trailing P/E of -1.4x. Analysts expect EPS to grow +50.8% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
PHGEBiomX Inc. | $1.2B | $0.45 | $38.00 | +7209.1% | Buy | — | 5 |
LSTALisata Therapeutics, Inc. | $32M | $3.47 | — | — | — | — | — |
SIGASIGA Technologies, Inc. | $311M | $4.33 | — | — | Buy | 2.5x | 1 |
ACXPAcurx Pharmaceuticals, Inc. | $2M | $1.51 | — | — | — | — | — |
INNVInnovAge Holding Corp. | $1.2B | $9.21 | $6.80 | -24.2% | Hold | 83.0x | 8 |
PRAXPraxis Precision Medicines, Inc. | $8.8B | $303.00 | $584.00 | +106.9% | Buy | — | 16 |
AGENAgenus Inc. | $127M | $3.04 | $7.33 | +144.3% | Buy | 3.8x | 11 |
ADMAADMA Biologics, Inc. | $2.0B | $8.57 | $21.00 | +152.7% | Buy | 10.0x | 10 |
ICLRICON Public Limited Company | $10.8B | $140.73 | $139.90 | -4.2% | Buy | 13.8x | 30 |
CRLCharles River Laboratories International, Inc. | $8.7B | $181.56 | $214.14 | +15.8% | Buy | 16.7x | 37 |
Quick answers to the most common questions about buying ARMP stock.
The consensus Wall Street price target for ARMP is $15, representing 111.9% upside from the current price of $6.87. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ARMP has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $15 implies 111.9% upside from current levels.
ARMP's current price is $6.87 with a consensus target of $15 (111.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $15 for ARMP, while the most conservative target is $15. The consensus of $15 represents the median expectation. These targets typically reflect 12-month expectations.
ARMP is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ARMP stock forecast based on 4 Wall Street analysts shows a consensus price target of $15, with estimates ranging from $15 (bear case) to $15 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on ARMP, with a "Buy" consensus rating and $15 price target (111.9% upside). 4 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ARMP analyst price targets range from $15 to $15, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $15 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.